AllantoinvsHyaluronic Acid

Allantoin (5-ureidohydantoin) stimulates cell proliferation and tissue regeneration by promoting fibroblast activity, keratinocyte proliferation, and extracellular matrix synthesis including collagen and glycosaminoglycans. It acts as a mild keratolytic by promoting the natural desquamation process—loosening corneocyte adhesion and facilitating shedding—without the irritation, pH disruption, or barrier compromise associated with alpha- or beta-hydroxy acids. Allantoin has anti-inflammatory properties through modulation of prostaglandin synthesis (inhibiting COX-2 and reducing PGE2) and may downregulate pro-inflammatory cytokines. Its moisturizing effect comes from increasing the water-binding capacity of the extracellular matrix and stratum corneum; it is highly soluble and forms hydrogen bonds with water. Allantoin also promotes wound epithelialization. Its safety profile—non-irritating, non-sensitizing, non-comedogenic—makes it suitable for compromised skin, post-procedure care, and infant formulations.

Hyaluronic acid is a glycosaminoglycan (GAG) composed of repeating D-glucuronic acid and N-acetyl-D-glucosamine disaccharides. Its hydroxyl and carboxyl groups create strong hydrogen bonding with water—each molecule binds up to 1000x its weight in water. High molecular weight HA (>1000 kDa) forms a viscoelastic film on the stratum corneum, reducing transepidermal water loss (TEWL). Medium weight (100-1000 kDa) penetrates the upper epidermis. Low molecular weight HA (<100 kDa) reaches the dermis and binds CD44 and RHAMM receptors on fibroblasts, triggering ERK and PI3K signaling that stimulates fibroblast proliferation, hyaluronan synthase (HAS2) expression, and collagen I/III synthesis. Sodium hyaluronate—the salt form—has improved stability and penetration. Multi-weight formulations provide surface hydration and deeper dermal stimulation.